metoprolol has been researched along with Heart Failure, Systolic in 6 studies
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.
Heart Failure, Systolic: Heart failure caused by abnormal myocardial contraction during SYSTOLE leading to defective cardiac emptying.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metoprolol CR/XL was well tolerated in all 3 renal function subgroups." | 6.74 | The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF). ( Fagerberg, B; Ghali, JK; Goldstein, S; Hjalmarson, A; Johansson, P; Kjekshus, J; Ohlsson, L; Samuelsson, O; Van Veldhuisen, DJ; Waagstein, F; Wedel, H; Wikstrand, J, 2009) |
| "We analyzed outcomes in SHIFT patients with systolic heart failure who were prescribed β-blockers (carvedilol, bisoprolol, metoprolol, or nebivolol) with ivabradine or placebo." | 5.20 | Effect of Combining Ivabradine and β-Blockers: Focus on the Use of Carvedilol in the SHIFT Population. ( Bocchi, EA; Böhm, M; Borer, JS; Ford, I; Komajda, M; Swedberg, K; Tavazzi, L, 2015) |
| "Metoprolol CR/XL was well tolerated in all 3 renal function subgroups." | 2.74 | The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF). ( Fagerberg, B; Ghali, JK; Goldstein, S; Hjalmarson, A; Johansson, P; Kjekshus, J; Ohlsson, L; Samuelsson, O; Van Veldhuisen, DJ; Waagstein, F; Wedel, H; Wikstrand, J, 2009) |
| "8 months was analysed with respect to beta blocker dosing and resting HR." | 1.48 | Beta blockers and chronic heart failure patients: prognostic impact of a dose targeted beta blocker therapy vs. heart rate targeted strategy. ( Corletto, A; Frankenstein, L; Fröhlich, H; Hochadel, M; Katus, HA; Kilkowski, C; Senges, J; Täger, T; Winkler, R; Zahn, R, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Corletto, A | 1 |
| Fröhlich, H | 1 |
| Täger, T | 1 |
| Hochadel, M | 1 |
| Zahn, R | 1 |
| Kilkowski, C | 1 |
| Winkler, R | 1 |
| Senges, J | 1 |
| Katus, HA | 1 |
| Frankenstein, L | 1 |
| Wikstrand, J | 2 |
| Wedel, H | 2 |
| Castagno, D | 1 |
| McMurray, JJ | 1 |
| Bocchi, EA | 1 |
| Böhm, M | 1 |
| Borer, JS | 1 |
| Ford, I | 1 |
| Komajda, M | 1 |
| Swedberg, K | 1 |
| Tavazzi, L | 1 |
| Ghali, JK | 1 |
| Van Veldhuisen, DJ | 1 |
| Fagerberg, B | 1 |
| Goldstein, S | 1 |
| Hjalmarson, A | 1 |
| Johansson, P | 1 |
| Kjekshus, J | 1 |
| Ohlsson, L | 1 |
| Samuelsson, O | 1 |
| Waagstein, F | 1 |
| Ong, HT | 1 |
| Kow, FP | 1 |
| Albert, NM | 1 |
1 review available for metoprolol and Heart Failure, Systolic
| Article | Year |
|---|---|
Switching to once-daily evidence-based [beta]-blockers in patients with systolic heart failure or left ventricular dysfunction after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Algorithms; Carbazoles; Carvedilol; Delayed-Action Preparations; Eviden | 2007 |
2 trials available for metoprolol and Heart Failure, Systolic
| Article | Year |
|---|---|
Effect of Combining Ivabradine and β-Blockers: Focus on the Use of Carvedilol in the SHIFT Population.
Topics: Adrenergic beta-Antagonists; Aged; Benzazepines; Bisoprolol; Carbazoles; Cardiovascular Agents; Carv | 2015 |
The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF).
Topics: Adrenergic beta-Antagonists; Aged; Chronic Disease; Feeding Behavior; Female; Glomerular Filtration | 2009 |
3 other studies available for metoprolol and Heart Failure, Systolic
| Article | Year |
|---|---|
Beta blockers and chronic heart failure patients: prognostic impact of a dose targeted beta blocker therapy vs. heart rate targeted strategy.
Topics: Adrenergic beta-Antagonists; Carvedilol; Cause of Death; Female; Follow-Up Studies; Germany; Heart F | 2018 |
The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Delayed-A | 2014 |
Beta-blockers for heart failure: why you should use them more.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carved | 2011 |